Objectives: To determine the prevalence of inferred low-frequency HIV-1 transmitted drug resistance (TDR) in MSM in the UK and its predicted effect on first-line therapy.
Introduction
Drug resistance mutations identified in newly diagnosed, treatment-naive patients are presumed to be a result of the transmission of drug-resistant variants. Transmitted drug resistance (TDR) can limit the treatment options available to newly diagnosed HIV-1-positive patients and is associated with an increased risk of virological failure. 1, 2 The prevalence of TDR in the UK has been estimated by analysing the earliest available sequences from all treatment-naive patients or from seroconverters submitted to the UK HIV drug resistance database matched to the national new HIV diagnoses database. 3 -7 The sequences are generated using Sanger capillary sequencing, which has a limit of detection of 20% of variant frequency present in the viral population. Using these data, the prevalence of HIV-1 TDR in the UK appeared to have peaked at 13% in 2002, before declining to a nadir of 6.6% in 2013. 8, 9 However, the level of TDR has been consistently higher in MSM and has been shown to be more likely in MSM infected with subtype B compared with other exposure groups. 8, 10 The prevalence of TDR in the MSM group in the UK was estimated at 15.2% at its peak in 2002 before declining to its lowest level in 2013 at 7.5%. 11 The MSM risk group also bears the highest burden of the infection, accounting for 54% of new diagnoses and 41% of people living with HIV in the UK in 2013. 11 Following transmission, and in the absence of drug pressure, drug resistance mutations may revert to WT or an intermediate form due to the reduced replicative capacity of viruses with particular mutations. 12 Some drug resistance mutations may also persist in latently infected cells or become compartmentalized, reappearing later in the presence of antiretroviral (ARV) drugs. 13, 14 A number of studies have been conducted to determine the persistence of TDR. 15 -18 However, the persistence of TDR mutations has been shown to vary between particular types of mutations. 19 In addition, some mutations may fall # Crown copyright 2016.
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J Antimicrob Chemother 2017; : 227-234 72 Advance Access publication 14 October 2016 below the limit of detection of Sanger capillary sequencing and this may have an impact on the response to ART as these lowfrequency variants could re-emerge upon initiation of therapy, resulting in treatment failure. 20 -22 The development of next-generation sequencing (NGS) technologies has allowed the detection of low-level drug resistance mutations present in a viral population at frequencies as low as 0.3%. 23 Recent studies employing sensitive genotyping assays have shown that the prevalence of TDR can be as high as 30%. 24, 25 However, several studies examining the clinical significance of low-frequency variants on treatment outcome have shown that not all low-frequency drug-resistant variants detected in treatment-naive individuals contribute to virological failure. 26 This study applied NGS to samples from patients deemed to have been infected within 6 months of sampling by the application of a recent infection testing algorithm (RITA). 27 Not only does this increase the potential to detect TDR mutations before they revert or are archived, as previously done using seroconverter cohorts, 4 -6 but importantly increases the likelihood of detecting low-frequency variants. Additionally, since the national reference laboratory in England applies this RITA to 50% of all newly diagnosed HIV-1 infections as a population-level surveillance of HIV-1 incidence, these samples should also allow a more timely and direct measure of the prevalence of TDR and surveillance of circulating or emerging genotypes compared with samples from all newly HIV-1 diagnosed persons.
The work was conducted as part of the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) at University College London (UCL), a partnership with PHE in Blood Borne and Sexually Transmitted Infections in collaboration with the London School of Hygiene and Tropical Medicine.
Methods

Study population
The first plasma specimen from 442 newly HIV-1 diagnosed MSM sampled between July 2011 and December 2013 was analysed. This represents 42% of all samples identified to be likely recent infections during this period and 7% of all new infections among MSM as estimated by parsimonious back-calculation. 8, 28, 29 All patients were treatment-naive and identified as likely to be recently infected (within 6 months of infection) using RITA, which includes CD4+ count (.200 cells/mm 3 ), viral load (.1000 copies/mL) and the AxSYM HIV 1/2gO assay with an avidity index threshold ,80% or, for samples taken between September and December 2013, a limiting-antigen avidity assay with an OD index ,1.5. The assays differentiate likely recent from long-standing infection by the strength of HIV-specific antibody -antigen binding. 30, 31 The assays have a misclassification rate of ,5% and samples close to the avidity or OD index cut-off values are more likely to be misclassified. 32 Linked demographic and clinical information was extracted from the HIV and AIDS Reporting System held at PHE.
HIV-1 RNA extraction, PCR amplification and sequencing
Two hundred microlitres of each sample was used to extract viral RNA using the QIAamp UltraSens Virus Kit (QIAGEN) as per the kit instructions and the HIV-1 RNA eluted into 60 mL of AVE buffer. A 1.3 kb region of the HIV pol gene [whole of protease and N-terminal half of reverse transcriptase (RT); amino acids 1 -320] was amplified as previously described using 10 mL of the RNA extract in each PCR. 33 PCR products were purified using the QIAquick Kit (QIAGEN) and quantified using both Qubit w dsDNA Broad Range and High Sensitivity Assay Kits and the Qubit w 2.0 Fluorometer (Life Technologies). Then, 1 ng/mL of the amplified DNA product was used for DNA library preparation with the Nextera XT DNA Sample Prep Kit (Illumina) as per the kit protocol. NGS was performed using the MiSeq Reagent Kit version 2 (Illumina).
Bioinformatic analysis
A subset of the MiSeq paired-end reads from each FASTQ file was compared with a local database of HIV reference sequences using BLAST to identify an optimum reference sequence for mapping using BWA-MEM version 0.7.5. Utilizing SAMTools, the resulting files were then converted into BAM format in preparation for in-house-developed software, QuasiBAM, which generates consensus sequences of the protease and RT regions and produces detailed information on the frequencies of minority variants present within each sample. These procedures were automated using a computational pipeline developed in-house using Python and C++.
Analysis of HIV-1 subtypes, TDR and predicted drug susceptibility HIV-1 subtypes were determined using four publically available HIV-1 subtyping tools: REGA HIV-1 Subtyping Tool (version 3.0), SCUEAL algorithm, jumping profile Hidden Markov Model ( jpHMM-HIV) and Context-based Modelling for Expeditious Typing (COMET HIV-1). 34 -38 When the subtyping tools were discordant, the subtype or circulating recombinant form (CRF) was called by manual inspection or designated as a unique recombinant form (URF) if it could not be assigned to a particular subtype or CRF. TDR mutations were defined using the WHO 2009 list of surveillance drug resistance mutations. 39 The drug susceptibility of each sample was determined using the Stanford HIV drug resistance database genotypic interpretation algorithm version 7.0. 40 
Statistical analyses
Upper and lower 95% CIs were determined using the exact binomial calculation and estimates of the additional detections provided by the more sensitive 2%-20% test via McNemar's x 2 test for matched data. The association of subtype and other demographic factors (age, geographical region, ethnicity, country of birth and probable country of infection) with TDR rates was determined using univariate analysis involving OR and x 2 tests. Multivariable models were constructed to estimate the independent effects of covariates on TDR rates via logistic regression. Statistical analyses were carried out using Stata 13.1 software (StataCorp, College Station, TX, USA) or Microsoft Excel w , with a P value ,0.05 regarded as significant.
Sequence data
Sequences from this study containing TDR have been submitted to GenBank and may be accessed by the following accession numbers: KX759447 -KX759516.
Results
Characterization of the study population
From July 2011 to December 2013, 58.1% (4119/7093) of newly HIV-1 diagnosed MSM in England, Wales and Northern Ireland were tested using RITA by the national reference laboratory in England (Table 1) . Of these, 26.7% (1101) were identified as likely recent infections, of which 442 had sufficient residual volume and were successfully amplified by PCR and subjected to NGS. This represents 40.1% of all RITA positive samples during that period. Samples included 68 from 2011, 145 from 2012 and 229 from Cunningham et al. 2013 . The median age of the study population was 32 years (IQR 26-40). More than half of the newly diagnosed (51.4%) were from the London region; however, the proportions that were RITA tested and found to be recently infected and then sequenced was similar across the geographical regions, ranging from 39.0% to 43.9%. In contrast, a higher proportion (44.9%) of samples from the recently infected .50-year-olds were sequenced compared with 33.8% from those aged between 15 and 24 years ( Table 1) .
Distribution of circulating HIV-1 subtypes among recently infected MSM in the UK
The 442 sequences were subtyped using four web-based subtyping tools as described in the Methods section and the assigned subtypes are shown in Table 2 . For 402 sequences (91%), the results from at least three of the subtyping tools were concordant and the results for 425 sequences (96.2%) were concordant by at least two subtyping tools. The remaining sequences, where the subtyping tools disagreed or returned no particular assignment, were mostly complex URFs. As expected, subtype B was the predominant subtype making up 75.6%. Of note, the most common non-B subtype group consisted of rare CRFs and URFs at 6.6%. The majority (27/29) of the rare CRFs/URFs were composed of a subtype B and another subtype(s) or CRFs (Table S1 , available as Supplementary data at JAC Online). The subtypes of the remaining samples in order of abundance were subtypes F1 (4.5%, n ¼20), CRF02_AG (4.3%, n ¼ 19), A1 (3.4%, n ¼ 15), C (2.3%, n ¼ 10), CRF01_AE (1.4%, n¼ 6), CRF06_cpx (1.4%, n ¼ 6), G (0.5%, n ¼ 2) and CRF07_BC (0.2%, n¼ 1).
Proportion of TDR at 20% variant frequency threshold
We determined the proportion of TDR mutations among recently infected MSM at a variant frequency threshold of .20%, which is equivalent to that used for Sanger capillary sequencing. At this threshold, TDR mutations were detected in 32 out of the 442 sequences (7.2%; 95% CI 5.0% -10.1%). By drug class, the overall TDR proportion was as follows: PIs (2.7%, n ¼ 12), NRTIs (3.2%, n ¼ 14) and NNRTIs (1.6%, n ¼ 7). The TDR mutations detected in the 32 sequences are shown in Table 3 . One sample had dual-class resistance with three mutations, two NRTI mutations (M41L and M184V) and one NNRTI mutation (V106A). The remainder had single-class resistance with one TDR mutation each except for one sample that had two NNRTI mutations (K103N and Y188L). The most common TDR mutations detected in each class were: L90M (n ¼ 7) for PIs, T215rev (n ¼ 9) for NRTIs and K103N (n ¼ 5) for NNRTIs (Table 3) . Two NNRTI mutations present in one sample (K103N and Y188L). HIV-1 low-frequency TDR variants
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Detection of low-frequency TDR mutations between 2% and 20% mutation frequency thresholds
To establish the threshold for detection of low-level variants in our assay, we determined the reproducibility of the detection of variants in clinical samples. We compared the frequency of each codon in the pol gene amplicon of a particular sample with its corresponding codon in a replicate that had been processed independently from nucleic acid extraction to sequencing. This showed that some codons detected at low frequencies did not have the same percentage occurrence in the two independent runs and this was seen more often with variants detected at ,2% (Figure 1a) . Furthermore, the analysis showed that if we included frequencies in the second replicate at plus or minus 50% of the value of the first replicate, the threshold of lowfrequency variant detection approaches 100% only at cut-off values .2% (Figure 1b) . The median depth of coverage for each replicate run was similar and high at 15 782 (IQR 11 426 -19 502) and 19393 (15 375-22 454) for runs 1 and 2, respectively ( Figure 1c) . Thus, the threshold for low-frequency variant detection in our assay was set at 2%. At the 2% variant frequency threshold, an additional 38 samples were identified to have TDR mutations, representing a significant increase in the overall TDR proportion at 15.8% (95% CI 12.6% -19.6%) (McNemar's x 2 P,0.0001). The depth of coverage at sites where low-frequency variants were identified was very high and ranged from 7139 to 47 752 reads (Table S2) . By drug class, the overall TDR proportions when low-frequency variants were included increased by 3.2-fold for PIs at 8.6%, by 1.7-fold for NRTIs at 5.4% and by 1.9-fold for NNRTIs at 2.9%. Low-frequency variants were detected in four samples that had TDR mutations at a frequency .20%: PI V82A + NNRTI K103N (9.7%); NNRTI K103N and Y188L + PI M46L (2.1%); NRTI T215S+ PI M46L (11%); and PI L90M + PI D30N (5.9%). This changed the classification of the first three samples from single-to dual-class resistance. The majority of the identified low-frequency variants were PI mutations that were detected in 26 out of 42 (62%) samples (Table 3 and Table S2 ).
Factors associated with TDR
Univariable analyses revealed that TDR was significantly associated with subtype B compared with non-B infections (OR ¼ 0.41 for TDR in non-B subtype infections; 95% CI ¼ 0.19 -0.85; P ¼ 0.017). This was mostly due to a reduced likelihood of TDR in non-B subtype infections at .20% variant frequency (OR ¼ 0.30; 95% CI ¼ 0.09 -1.01; P ¼ 0.051 compared with OR¼0.59; 95% CI¼0.26-1.37; P ¼0.223 at 2%-20% variant frequency). Multivariable analyses confirmed subtype as an independent factor associated with TDR (OR ¼ 0.38 for TDR in non-B subtype infections; 95% CI ¼ 0.17 -0.88; P ¼ 0.024). The only other factor significantly associated with TDR in multivariable analyses was infections that were probably acquired outside the UK (OR ¼ 2.64; 95% CI ¼ 1.03 -6.78; P ¼ 0.044). However, this effect was slightly attenuated in univariable analyses (OR ¼ 2.12; 95% CI¼0.93-4.83; P¼ 0.073) and was not strongly linked with a particular variant frequency threshold. There was no significant association with age, geographical region, ethnicity and the country of birth in both univariable and multivariable analyses (Table 4) .
Predicted susceptibility of samples harbouring low-frequency variants to ARVs recommended for first-line therapy in the UK
We investigated the predicted effect of the low-frequency TDR mutations detected on susceptibility to the ARVs that are currently recommended for first-line treatment or as alternatives in the UK. 41 The susceptibility of the samples was analysed using the Stanford HIV drug resistance database genotypic interpretation algorithm, which assigns five different levels of drug susceptibility: susceptible, potential resistance, low-level resistance, intermediate resistance (Figure 2 ). At the .20% variant frequency threshold, the drugs most affected were as follows: the NNRTIs nevirapine and efavirenz with 1.9%, the NRTI zidovudine with 2.5% and the PIs atazanavir and lopinavir with 1.7% of the samples showing low-to high-level resistance (Figure 2 ). The only drugs not associated with any resistance were the PI darunavir and the NRTI tenofovir. When the lowlevel frequency mutations were included, we observed an increase in the proportion of samples with reduced susceptibility to all drugs including resistance to darunavir and tenofovir (Figure 2 ). Resistance to the NNRTIs nevirapine and efavirenz increased 2-fold to 4% and 3.8%, respectively, whereas that to the PIs lopinavir and atazanavir increased 2.3-and 2.8-fold to 4.6% and 3.8%, respectively. Of note, a significant proportion of the samples showed resistance to PIs and NRTIs that are no longer used in the UK, with 2.7% of the samples showing resistance to the older NRTIs and PIs at the .20% variant frequency threshold increasing up to 8% at the .2% variant frequency threshold.
Discussion
The data show that the proportion of TDR among recently infected MSM doubles when low-frequency variants are taken into account, from 7.2% to 15.8% at the .20% and .2% variant frequency thresholds, respectively. This is in agreement with other studies that have used highly sensitive genotyping methods where the proportion of TDR among treatment-naive individuals has ranged between 17% and 30% worldwide. 20,23,26,42 -44 The majority (62%) of the low-frequency variants were associated with resistance to PIs despite PI-associated drug resistance mutations rarely being observed among treatment-experienced patients failing therapy in the UK at 3.5% in 2013 compared with 16.5% and 23.2% for NRTI and NNRTI mutations (UK HIV Drug Resistance Database -http://hivrdb.org.uk/). It is expected that following transmission, drug resistance-associated variants would steadily decline and disappear with time in the absence of drug selective pressure. Thus, these data suggest either transmission and sustained persistence of low-frequency variants or stochastic de novo generation of these mutations in the infected patients. For the latter, the mutations would be expected to be randomly distributed; however, the data show a predominance of particular types of low-frequency variants in each drug class, i.e. M46IL for PIs, D67GN for NRTIs and G190E for NNRTIs, which are different from the most common drug resistance-associated mutations observed at the .20% variant frequency threshold: L90M, T215rev and K103N, respectively. Alternatively, this could reflect the impact on replication fitness of individual mutations with those significantly detrimental to viral replication most likely to decrease rapidly in frequency in the absence of drug selection or it could be dependent on differences in the frequency of a given codon change resulting in an amino acid substitution at a particular site.
Several studies have investigated the transmission of lowfrequency drug-resistant variants. 45 -47 One study using ultradeep HIV-1 low-frequency TDR variants JAC sequencing on samples from 32 recently infected individuals concluded that the bulk of low-frequency drug-resistant variants were either due to sequencing or de novo viral replicative errors. 45 In contrast, a study using allele-specific PCR on samples from recently and chronically infected patients showed direct evidence that low-frequency variants can be transmitted. 46 It is possible that the contradictory outcomes could be a result of different experimental methodologies. Thus, the origins and source of these low-frequency variants need further investigation using large well-characterized cohorts, as it has been hypothesized that transmitted variants are more likely to persist and establish a latent infection than de novo-generated variants.
Similar to previous studies of TDR prevalence in the UK, the most common TDR mutations we identified at the .20% variant frequency threshold confer resistance to drugs no longer used for treatment of HIV-1 infection, i.e. PI L90M and NRTI T215rev. 9, 48 These mutations are likely to have been initially transmitted from ARV-experienced individuals further back in the transmission chain and despite absence of drug pressure have persisted in the population. 48, 49 Interestingly, TDR mutations, especially those present at a variant frequency .20%, were observed to significantly occur more frequently in subtype B than non-B subtypes in keeping with the notion that the resistance is mostly historical due to ART having been in use for longer in subtype B than non-B infections.
To date, studies describing the impact of low-frequency variants detected at baseline on treatment outcome have linked NNRTI resistance mutations with a 2-fold increase in the risk of virological failure. 21 One factor determined to be associated with this increased risk is the mutational load, which is a product of the frequency of the variant and viral load. 23, 50 Viral load data were incomplete for this study, but are likely to be relatively high for acute infections. However, we observed that the frequency of NNRTI low-frequency variants was often higher (between 3.1% and 15.4% and thus likely to represent a higher mutational load) compared with PI and NRTI variants that were mostly between 2% and 3% (Table S2) . Further large case -control or cohort studies are required to determine the impact of specific low-frequency variants on treatment outcome.
It has been reported that the proportion of non-B and non-C subtypes among the treatment-naive MSM population in the UK has increased significantly from 5.7% to 13.6% between 2002 and 2010. 51 In this study, this proportion was 22.2%, a further increase on the 2010 figures and in keeping with the upward trend in the proportion of non-B and non-C subtypes among MSM. We also show that rare CRFs/URFs were the most frequent non-B subtypes observed, composing 7% of the samples. This proportion is likely higher than reported here as only 15% of the genome was sequenced and recombination could have occurred in the non-sequenced portions. The increase in intersubtype recombinants could be due to increased migration from Africa and Eastern Europe, where they are more common, but could also reflect the emergence of novel recombinant forms due to an increased probability of intersubtype coinfections among MSM. The latter is supported by the fact that the majority of the rare recombinants were composed of subtype B and a non-B subtype or CRFs.
A limitation of this study is the threshold for detection of lowfrequency variants. As described earlier, the low-frequency variants detected in a sample could have several sources including real transmitted variants, variants introduced during de novo viral replication in vivo or laboratory artefacts introduced during RT-PCR amplification and/or sampling bias. Sampling bias occurs at several steps during the process: at RNA extraction, RT-PCR and DNA library preparation, all of which result in bottleneck effects. Laboratory artefacts and de novo viral replication errors have been shown to result in as high as 2% variant frequency using clinical samples from the pre-ART era. 52 By themselves, RT-PCR and sequencing errors on Illumina machines have been shown to account for 0.5% -1% of observed errors. 53, 54 Our experiments using repeat independent amplification and sequencing of the same clinical samples showed results that are consistent with these previous observations with most discrepancies in variant calls observed at frequencies ,2%. Therefore, the 2% threshold chosen for our assay probably results in the ruling out of most, if The susceptibility of each sample at ≥20% and .2% mutation frequency to licensed ARV drugs was predicted using the Stanford HIV drug resistance database genotypic interpretation algorithm. The graph shows the proportion of samples in each of the top three drug resistance levels used by the algorithm: low, intermediate and high level. The effects on drugs currently recommended for first-line treatment in the UK are shown individually, whereas the effects on older PI and NRTI drugs that are no longer used in first-line therapy (Old PIs and NRTIs) are shown together at the top of the graph. ZDV, zidovudine; ABC, abacavir; TDF, tenofovir; 3TC, lamivudine; FTC, emtricitabine, RPV, rilpivirine; NVP, nevirapine; EFV, efavirenz; ETR, etravirine; ATV, atazanavir; LPV, lopinavir; DRV, darunavir; Old PIs, fosamprenavir, indinavir, nelfinavir, saquinavir and tipranavir; Old NRTIs, stavudine and didanosine.
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not all, false positive variants (i.e. high specificity), but it is likely to result in undercalling of true variants (i.e. less sensitivity).
In summary, this study shows that the use of NGS can provide detailed and enhanced genomic information on TDR and subtype distribution in newly diagnosed HIV-1 patients as part of a national surveillance programme. These data gathered in real time together with demographic data and in tandem to determination of recently acquired infections are a useful extension to public health surveillance of HIV. The data can be used to better inform individual clinical prescribing practice, population-based prevention strategies and would also be useful for the validation of current diagnostic tools.
